Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Melanoma
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with...
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutionsFRIENDSWOOD, Texas--(BUSINESS...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for...
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid...
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid...
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics’ ARM-002 Anti-Cancer Vaccine
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or...
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,...
Sona’s Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model
Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
Defence’s AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech,...
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for...
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with...
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study
Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
ASTCT Supports the FDA’s Approval of Earlier Use of CAR T-Cell Therapy for Multiple Myeloma
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and the CAR T-Cell therapy Carvykti...